Kategorie: Genitourinární nádory
Téma: Poster session II: Genitourinary malignancies - Renal cancer
Číslo abstraktu: P-7128
Methods: Clinicians follow mRCC pts, for whom they have prescribed sorafenib, for the length of therapy, up to 12 months. Baseline characteristics are recorded and at pts' normally scheduled follow-up visits, tumor status, pt status, and adverse events (AEs) are noted.
Results: Currently 1529 pts are valid for baseline characteristics; 91% were prescribed sorafenib 400 mg bid. The table shows baseline characteristics in PREDICT compared to TARGET. While the most frequently reported AEs were similar in the two sorafenib-treated populations, incidences were lower in PREDICT (valid for safety: N = 1606) vs TARGET (N = 451), ie, hand-foot skin reaction (22% vs 30%), diarrhea (18% vs 43%), rash (10% vs 40%), and alopecia (7% vs 27%).
Conclusions: These initial findings of PREDICT show that the safety profile of sorafenib is similar to that seen in the research setting of TARGET. However, pts in the real-world setting of PREDICT have a somewhat worse baseline tumor/disease condition and prognosis.
Publikováno v: European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 431
Datum přednesení příspěvku: 21. 9. 2009